1401067-00-2

Basic information

• Product Name: (4S)-4-(propan-2-yl)-3-(5,5,5-trifluoropentanoyl)-1,3-oxazolidin-2-one
• CAS NO: 1401067-00-2
• Molecular Weight: 267.248
• Mol File: 1401067-00-2.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: (4S)-4-(propan-2-yl)-3-(5,5,5-trifluoropentanoyl)-1,3-oxazolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (4S)-4-(propan-2-yl)-3-(5,5,5-trifluoropentanoyl)-1,3-oxazolidin-2-one(1401067-00-2)
• EPA Substance Registry System: (4S)-4-(propan-2-yl)-3-(5,5,5-trifluoropentanoyl)-1,3-oxazolidin-2-one(1401067-00-2)

Safety Data

• Hazardous Substances Data: 1401067-00-2(Hazardous Substances Data)

Usage

Description

(4S)-4-(propan-2-yl)-3-(5,5,5-trifluoropentanoyl)-1,3-oxazolidin-2-one, also known as TAZIFYL, is a cyclic enol ether with a unique structure that features an oxazolidinone ring and a trifluoropentanoyl group. (4S)-4-(propan-2-yl)-3-(5,5,5-trifluoropentanoyl)-1,3-oxazolidin-2-one has potential applications in the pharmaceutical and agrochemical industries due to its structural and chemical properties.

Uses

Used in Pharmaceutical Industry:
(4S)-4-(propan-2-yl)-3-(5,5,5-trifluoropentanoyl)-1,3-oxazolidin-2-one is used as a building block for drug discovery and development. Its unique structure and the presence of fluorine atoms can enhance the bioavailability and metabolic stability of potential drug candidates, making it a valuable compound for the creation of new medications.
Used in Agrochemical Industry:
(4S)-4-(propan-2-yl)-3-(5,5,5-trifluoropentanoyl)-1,3-oxazolidin-2-one is used as a compound in the synthesis of various organic compounds, which can be applied in the development of new agrochemicals. Its unique properties may contribute to the creation of more effective and environmentally friendly products for agricultural use.

Upstream product

• 407-62-5 5,5,5-trifluoropentanoic acid 
• 17016-83-0 (4S)-4-isopropyl-1,3-oxazolidin-2-one 
• 1186202-35-6 5,5,5-trifluoro-n-valeryl chloride 

Downstream Products

• 1581704-47-3 (2R,3S)-N-((3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-N’(1-piperidinylmethyl)-2,3-bis(3,3,3-trifluoropropyl)succinamide 
• 1581704-46-2 (2R,3S)-N-((3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-N’((4-methyl-1-piperazinyl)methyl)-2,3-bis(3,3,3-trifluoropropyl)succinamide 
• 1581704-45-1 methyl S-(((2S,3R)-6,6,6-trifluoro-3-(((3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-L cysteinate 
• 1581704-44-0 (2S,3R)-N-((2-(Dimethylamino)ethyl)sulfanyl)-N’-((3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide 
• 1581704-43-9 S-(((2S,3R)-6,6,6-trifluoro-3-(((3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-L-cysteine 
• 1581704-42-8 (2S,3R)-N-((2-Aminoethyl)sulfanyl)-N’-((3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide 
• 1581704-66-6 tert-butyl 2-((2S,3R)-6,6,6-trifluoro-3-((S,Z)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-ylcarbamoyl)-2-(3,3,3-trifluoropropyl)hexanamidothio) ethylcarbamate 
• 1581704-41-7 (2S,3R)-N-((isobutylamino)methyl)-N’-((3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide 
• 1401066-79-2 (2R,3S)-N-((3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3- trifluoropropyl)succinamide 
• 1401067-34-2 (2S,3R)-6,6,6-trifluoro-3-((⁽³⁵⁾-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoic acid 
• 1401067-05-7 tert-butyl (2S,3R)-6,6,6-trifluoro-3-(((3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoate 
• 1401067-06-8 tert-butyl (2R,3R)-6,6,6-trifluoro-3-((⁽³⁵⁾-1-methyl-2-oxo-5-phenyl2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoate 
• 1581704-53-1 (2R,3S)-N-((3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-N’(1-pyrrolidinylmethyl)-2,3-bis(3,3,3-trifluoropropyl)succinamide 
• 1581704-52-0 C₃₃H₄₀F₆N₆O₃ 

Relevant articles and documents

Discovery of clinical candidate BMS-906024: A potent pan-notch inhibitor for the treatment of leukemia and solid tumors

Structure-activity relationships in a series of (2-oxo-1,4-benzodiazepin-3-yl)-succinamides identified highly potent inhibitors of γ-secretase mediated signaling of Notch1/2/3/4 receptors. On the basis of its robust in vivo efficacy at tolerated doses in

SUBSTITUTED 1,5-BENZODIAZEPINONE COMPOUNDS

Disclosed are compounds of Formula (I): wherein: R1 is CH2CH2CF3; R2 is CH2CH2CF3, CH2(cyclopropyl), or phenyl; R3 is H or CH3; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.

PRODRUGS OF 1,4-BENZODIAZEPINONE COMPOUNDS

Disclosed are compounds of Formula (I) and salts thereof, wherein: a) R1 is H or CH3, and R2 is Ry; or b) R1 is Rx and R2 is H; wherein Rx and Ry are disclosed herein.